Metoprolol Succinate Tablet, Extended Release
Product Images NDC 27808-302

This text presents data on the total mortality and subgroup analysis results from a study involving Wetoprolol Succinate Extended-Release Tablets in patients with heart failure. The study evaluated the benefits of Wetoprolol over placebo in terms of mortality and hospitalization due to heart failure events. Subgroups examined include patients with ischemic and non-ischemic etiology, male and female patients, Caucasians and Blacks, as well as individuals with or without a history of myocardial infarction, diabetes mellitus, and hypertension. Information is also provided on heart rate categories and the relative risk associated with myocardial infarction. Overall, the study used data from the MERIT-HF trial to assess the effectiveness of Wetoprolol Succinate in reducing mortality and hospitalization for heart failure.*

The text is not clear to generate a description.*

This text provides information about Metoprolol Succinate Extended-Release Tablets. Each tablet contains 95 mg of metoprolol succinate USP equivalent and 100 mg of metoprolol tartrate USP. The dosage and usage instructions are available in the insert. It is advised to store the tablets at a temperature between 15-25°C (59-77°F) with excursions permitted up to 30°C (86°F). The tablets should be protected from moisture. The manufacturer is Visum Pharmaceutical Co. in China, distributed by Cranbury Pharmaceuticals in Monmouth Junction, NJ. The warning to keep medications away from children is also highlighted.*

This text includes information about a medication called Metoprolol Succinate Extended-Release Tablets, USP. It contains 250mg of Metoprolol Succinate and is to be stored at 25 degrees Celsius. The medication should be kept out of reach of children and pets. The manufacturer is not clearly indicated in this text.*